Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.

نویسندگان

  • Ali Amin Al Olama
  • Sara Benlloch
  • Antonis C Antoniou
  • Graham G Giles
  • Gianluca Severi
  • David E Neal
  • Freddie C Hamdy
  • Jenny L Donovan
  • Kenneth Muir
  • Johanna Schleutker
  • Brian E Henderson
  • Christopher A Haiman
  • Fredrick R Schumacher
  • Nora Pashayan
  • Paul D P Pharoah
  • Elaine A Ostrander
  • Janet L Stanford
  • Jyotsna Batra
  • Judith A Clements
  • Suzanne K Chambers
  • Maren Weischer
  • Børge G Nordestgaard
  • Sue A Ingles
  • Karina D Sorensen
  • Torben F Orntoft
  • Jong Y Park
  • Cezary Cybulski
  • Christiane Maier
  • Thilo Doerk
  • Joanne L Dickinson
  • Lisa Cannon-Albright
  • Hermann Brenner
  • Timothy R Rebbeck
  • Charnita Zeigler-Johnson
  • Tomonori Habuchi
  • Stephen N Thibodeau
  • Kathleen A Cooney
  • Pierre O Chappuis
  • Pierre Hutter
  • Radka P Kaneva
  • William D Foulkes
  • Maurice P Zeegers
  • Yong-Jie Lu
  • Hong-Wei Zhang
  • Robert Stephenson
  • Angela Cox
  • Melissa C Southey
  • Amanda B Spurdle
  • Liesel FitzGerald
  • Daniel Leongamornlert
  • Edward Saunders
  • Malgorzata Tymrakiewicz
  • Michelle Guy
  • Tokhir Dadaev
  • Sarah J Little
  • Koveela Govindasami
  • Emma Sawyer
  • Rosemary Wilkinson
  • Kathleen Herkommer
  • John L Hopper
  • Aritaya Lophatonanon
  • Antje E Rinckleb
  • Zsofia Kote-Jarai
  • Rosalind A Eeles
  • Douglas F Easton
چکیده

BACKGROUND Genome-wide association studies have identified multiple genetic variants associated with prostate cancer risk which explain a substantial proportion of familial relative risk. These variants can be used to stratify individuals by their risk of prostate cancer. METHODS We genotyped 25 prostate cancer susceptibility loci in 40,414 individuals and derived a polygenic risk score (PRS). We estimated empirical odds ratios (OR) for prostate cancer associated with different risk strata defined by PRS and derived age-specific absolute risks of developing prostate cancer by PRS stratum and family history. RESULTS The prostate cancer risk for men in the top 1% of the PRS distribution was 30.6 (95% CI, 16.4-57.3) fold compared with men in the bottom 1%, and 4.2 (95% CI, 3.2-5.5) fold compared with the median risk. The absolute risk of prostate cancer by age of 85 years was 65.8% for a man with family history in the top 1% of the PRS distribution, compared with 3.7% for a man in the bottom 1%. The PRS was only weakly correlated with serum PSA level (correlation = 0.09). CONCLUSIONS Risk profiling can identify men at substantially increased or reduced risk of prostate cancer. The effect size, measured by OR per unit PRS, was higher in men at younger ages and in men with family history of prostate cancer. Incorporating additional newly identified loci into a PRS should improve the predictive value of risk profiles. IMPACT We demonstrate that the risk profiling based on SNPs can identify men at substantially increased or reduced risk that could have useful implications for targeted prevention and screening programs.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of the ELAC2 Ser217Leu and Ala541Thr Polymorphisms in the Patients with Prostate Cancer

Introduction: Prostate cancer is the fifth most common cancer in the world and the second leading cause of cancer death among men. The ELAC2 gene (HPC2 locus) on chromosome 17p11 has been identified as hereditary tumor suppressor genes in prostate cancer. Some evidence showed that ELAC2 Ser217Leu and Ala541Thr polymorphisms were associated with prostate cancer risk. The aim of this study was to...

متن کامل

بررسی نقش ژن CYP1B1 در سرطان پروستات در دو جمعیت ایرانی و هندی

 Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of cancer death among men in the world. Growth, maintenance and the expression of genes involved in the production of steroids, may alter the susceptibility of prostate cancer. One such gene, CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1) is involved in the activation of many carcinogens and i...

متن کامل

اثر ایمونوتراپی سرطان پروستات بر بیان ژنesp انتروکوکوس فکالیس

Background: Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer deaths among men in the world. Immunotherapy is a new, non-invasive and effective method for the treatment of cancer, but its side effects on the normal flora of bacteria and opportunistic infections not known yet. The aim of this study was to evaluate the effects of immunotherapy on Ent...

متن کامل

Association between prostate specific antigen change over time and prostate cancer recurrence risk: a joint model

Background: Prostate specific antigen (PSA) is an important biomarker to monitor patients after treated with radiation therapy (RT). The aim of this study is to evaluate the relationship between the PSA data and prostate cancer recurrence using the joint modeling. Methods: This historical cohort study was performed on 422 prostate cancer patients. Inclusion criteria included: patients with loc...

متن کامل

ژنتیک مولکولی، تشخیص، پیشگیری و ژن درمانی در سرطان پروستات:  مقاله مروری

The prostate is a small gland located below the bladder and upper part of the urethra. In developed countries prostate cancer is the second common cancer (after skin cancer), and also the second leading cause of cancer death (after lung cancer) among men. The several studies have been shown prostate cancer familial aggregation. The main reason for this aggregation is inheritance included genes....

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

دوره 24 7  شماره 

صفحات  -

تاریخ انتشار 2015